BalanceD-HF
a Phase III, randomised, Double-blind study to evaluate the effect of Balcinrenone/Dapagliflozin, compared with dapagliflozin, on the risk of heart failure events and cardiovascular death in patients with heart failure and impaired kidney function
- Stage
- inclusie
- Medicine
- Balcinrenone/Dapagliflozine
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 15 August 2024
- Last Patient In
- 1 July 2026
- Last Patient Last Visit
- 1 August 2027
Inclusion period, 214 days remaining
National Lead
